Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Durvalumab
Sponsor: King Faisal Specialist Hospital & Research Center
Collaborators: AstraZeneca